Thrombocytopenia following sustained-release procainamide.
Procainamide hydrochloride-induced thrombocytopenia has infrequently been reported in the past. We report six cases of thrombocytopenia following the administration of the sustained-release form of procainamide. Three of these cases had platelet counts of less than 15,000/microL. The mean time to onset of thrombocytopenia from drug administration was 40 days (range, nine to 71 days). The mean time until normalization of the platelet counts after the drug therapy was stopped was 7.8 +/- 3.1 days (range, four to nine days). Oral prednisone therapy had little apparent benefit. The thrombocytopenia was not part of a systemic lupus erythematosus syndrome. We believe that thrombocytopenia is an important side effect of sustained-release procainamide therapy.
Meisner
D J
DJ
Carlson
R J
RJ
Gottlieb
A J
AJ
D000120:Acecainide / Q000097:blood; D000107:Acetylation; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D003692:Delayed-Action Preparations; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced; D008875:Middle Aged; D010641:Phenotype; D011342:Procainamide / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology; D013997:Time Factors
D000974:Antibodies, Antinuclear; D003692:Delayed-Action Preparations; D000120:Acecainide; D011342:Procainamide